LYBALVI is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Alkermes, Inc.. The primary component is Olanzapine; Samidorphan L-malate.
| Product ID | 65757-653_0e150f4e-3766-4ab0-8bb5-5f1224eada9c |
| NDC | 65757-653 |
| Product Type | Human Prescription Drug |
| Proprietary Name | LYBALVI |
| Generic Name | Olanzapine And Samidorphan L-malate |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2021-09-20 |
| Marketing Category | NDA / |
| Application Number | NDA213378 |
| Labeler Name | Alkermes, Inc. |
| Substance Name | OLANZAPINE; SAMIDORPHAN L-MALATE |
| Active Ingredient Strength | 15 mg/1; mg/1 |
| Pharm Classes | Atypical Antipsychotic [EPC],Opioid Antagonist [EPC],Opioid Antagonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-09-20 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 65757-651 | LYBALVI | olanzapine and samidorphan L-malate |
| 65757-652 | LYBALVI | olanzapine and samidorphan L-malate |
| 65757-653 | LYBALVI | olanzapine and samidorphan L-malate |
| 65757-654 | LYBALVI | olanzapine and samidorphan L-malate |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() LYBALVI 90765843 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2021-06-10 |
![]() LYBALVI 90765835 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2021-06-10 |
![]() LYBALVI 90538254 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2021-02-22 |
![]() LYBALVI 88489837 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2019-06-26 |
![]() LYBALVI 87700839 not registered Live/Pending |
Alkermes Pharma Ireland Limited 2017-11-29 |